Elbe Kliniken Stade-Buxtehude gGmbH

At Elbe Kliniken Stade-Buxtehude gGmbH in Buxtehude, the dermatology team is running a broad portfolio of studies in skin and connective tissue diseases. The main focus is on atopic dermatitis, psoriasis, hidradenitis suppurativa, prurigo nodularis, and bullous pemphigoid, with trials aimed at testing new therapies and improving long-term symptom control.

• Studies in moderate-to-severe atopic dermatitis, including research on symptom relief, disease control, and maintenance of treatment response
• Clinical research in plaque psoriasis and hidradenitis suppurativa focused on evaluating treatment effectiveness and skin improvement
• Trials in prurigo nodularis and bullous pemphigoid designed to reduce itching, inflammation, and persistent skin symptoms

This area reflects a strong interest in inflammatory skin disorders and in finding better options for patients with chronic, difficult-to-treat dermatologic conditions.

A major part of the trial activity at the site centers on melanoma and other neoplasms. The studies include patients with advanced melanoma, metastatic cutaneous melanoma, and solid tumors, with a clear emphasis on testing new immunotherapies and improving outcomes after surgery or in advanced disease.

• Research in advanced melanoma and metastatic melanoma aimed at improving disease control and delaying progression
• Studies in resected high-risk melanoma evaluating whether new treatments can lower the chance of recurrence
• Trials involving solid tumors and mutation-positive cancers focused on assessing anti-tumor activity and treatment benefit

The oncology work at Elbe Kliniken Stade-Buxtehude gGmbH is especially centered on checkpoint-based immunotherapy and combination approaches for patients with aggressive skin cancer.

The site also conducts substantial research in immune system diseases, particularly conditions driven by chronic inflammation or abnormal immune responses. Key areas include atopic dermatitis, chronic spontaneous urticaria, chronic inducible urticaria, and cutaneous lupus, with studies designed to assess safety, symptom reduction, and overall treatment effectiveness.

• Trials in chronic spontaneous urticaria and chronic inducible urticaria focused on controlling hives, itching, and provoked skin reactions
• Studies in cutaneous lupus erythematosus evaluating whether new treatment options can better reduce skin disease activity
• Investigations in atopic dermatitis and related immune-mediated skin disorders aimed at improving long-term disease management

These studies highlight a strong commitment to developing better therapies for patients with persistent immune-mediated skin disease and related inflammatory conditions.